{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T04:20:41Z","timestamp":1795062041309,"version":"4.10.2"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-63718-2","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:32:17Z","timestamp":1759249937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8514-8551","authenticated-orcid":false,"given":"Valerie S.","family":"Kalluri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8814-8004","authenticated-orcid":false,"given":"Brandon G.","family":"Smaglo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnan K.","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Kirtley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4092-4991","authenticated-orcid":false,"given":"Kathleen M.","family":"McAndrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayela","family":"Mendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana S.","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4020-385X","authenticated-orcid":false,"given":"Maria E.","family":"Salvatierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1253-630X","authenticated-orcid":false,"given":"Luisa M.","family":"Solis Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1317-9287","authenticated-orcid":false,"given":"Cara","family":"Haymaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Finch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2399-1375","authenticated-orcid":false,"given":"Mihai","family":"Gagea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"Fluty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-1574","authenticated-orcid":false,"given":"Steven J.","family":"Ludtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5469-9214","authenticated-orcid":false,"given":"J.","family":"Jack Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3268-514X","authenticated-orcid":false,"given":"Abhinav K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauri","family":"Varadhachary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0066-2672","authenticated-orcid":false,"given":"Rachna T.","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7923-9978","authenticated-orcid":false,"given":"Anirban","family":"Maitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9281-480X","authenticated-orcid":false,"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2190-547X","authenticated-orcid":false,"given":"Raghu","family":"Kalluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"63718_CR1","unstructured":"Society, A. C. Cancer Facts &Figures 2024. Atlanta: American Cancer Society (2024)."},{"key":"63718_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"63718_CR3","doi-asserted-by":"crossref","unstructured":"Ying, H., et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 30 (2024).","DOI":"10.1101\/gad.351863.124"},{"key":"63718_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","volume":"491","author":"AV Biankin","year":"2012","unstructured":"Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399\u2013405 (2012).","journal-title":"Nature"},{"key":"63718_CR5","doi-asserted-by":"crossref","unstructured":"Waters, A. M. & Der, C. J. KRAS: The critical driver and therapeutic target for pancreatic cancer. Cold spring harb perspect med 8 (2018).","DOI":"10.1101\/cshperspect.a031435"},{"key":"63718_CR6","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.devcel.2023.07.025","volume":"58","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan, K. K. et al. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8(+) T cells. Dev. Cell 58, 1562\u20131577 e1568 (2023).","journal-title":"Dev. Cell"},{"key":"63718_CR7","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","volume":"41","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan, K. K. et al. KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells. Cancer Cell 41, 1606\u20131620 e1608 (2023).","journal-title":"Cancer Cell"},{"key":"63718_CR8","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/2159-8290.CD-19-0297","volume":"10","author":"P Dey","year":"2020","unstructured":"Dey, P. et al. Oncogenic KRAS-driven metabolic reprogramming in pancreatic cancer cells utilizes cytokines from the tumor microenvironment. Cancer Discov. 10, 608\u2013625 (2020).","journal-title":"Cancer Discov."},{"key":"63718_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC Ozdemir","year":"2014","unstructured":"Ozdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719\u2013734 (2014).","journal-title":"Cancer Cell"},{"key":"63718_CR10","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","volume":"149","author":"H Ying","year":"2012","unstructured":"Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656\u2013670 (2012).","journal-title":"Cell"},{"key":"63718_CR11","doi-asserted-by":"crossref","unstructured":"Asimgil, H., et al. Targeting the undruggable oncogenic KRAS: the dawn of hope. JCI Insight 7 (2022).","DOI":"10.1172\/jci.insight.153688"},{"key":"63718_CR12","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1158\/0008-5472.CAN-24-1926","volume":"84","author":"AJ Aguirre","year":"2024","unstructured":"Aguirre, A. J., Stanger, B. Z. & Maitra, A. Hope on the horizon: a revolution in kras inhibition is creating a new treatment paradigm for patients with pancreatic cancer. Cancer Res 84, 2950\u20132953 (2024).","journal-title":"Cancer Res"},{"key":"63718_CR13","unstructured":"Chung, V., Mizrahi, J. D. & Pant, S. Novel therapies for pancreatic cancer. JCO Oncol Pract, OP2400279 (2024)."},{"key":"63718_CR14","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. KRAS(G12C) Inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med 383, 1207\u20131217 (2020).","journal-title":"N. Engl. J. Med"},{"key":"63718_CR15","doi-asserted-by":"crossref","unstructured":"Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes. Science 367 (2020).","DOI":"10.1126\/science.aau6977"},{"key":"63718_CR16","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1172\/JCI81135","volume":"126","author":"R Kalluri","year":"2016","unstructured":"Kalluri, R. The biology and function of exosomes in cancer. J. Clin. Invest 126, 1208\u20131215 (2016).","journal-title":"J. Clin. Invest"},{"key":"63718_CR17","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/j.1349-7006.2007.00506.x","volume":"98","author":"S Rejiba","year":"2007","unstructured":"Rejiba, S., Wack, S., Aprahamian, M. & Hajri, A. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci. 98, 1128\u20131136 (2007).","journal-title":"Cancer Sci."},{"key":"63718_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498\u2013503 (2017).","journal-title":"Nature"},{"key":"63718_CR19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99263","volume":"3","author":"M Mendt","year":"2018","unstructured":"Mendt, M. et al. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight 3, e99263 (2018).","journal-title":"JCI Insight"},{"key":"63718_CR20","doi-asserted-by":"publisher","first-page":"11717","DOI":"10.1021\/acsnano.3c12556","volume":"18","author":"KS Kapoor","year":"2024","unstructured":"Kapoor, K. S. et al. Single extracellular vesicle imaging and computational analysis identifies inherent architectural heterogeneity. ACS Nano 18, 11717\u201311731 (2024).","journal-title":"ACS Nano"},{"key":"63718_CR21","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1073\/pnas.1620861114","volume":"114","author":"H Mou","year":"2017","unstructured":"Mou, H. et al. Genetic disruption of oncogenic kras sensitizes lung cancer cells to fas receptor-mediated apoptosis. Proc. Natl Acad. Sci. USA 114, 3648\u20133653 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"63718_CR22","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1101\/gad.227413.113","volume":"27","author":"N Wajapeyee","year":"2013","unstructured":"Wajapeyee, N., Malonia, S. K., Palakurthy, R. K. & Green, M. R. Oncogenic RAS directs silencing of tumor suppressor genes through ordered recruitment of transcriptional repressors. Genes Dev. 27, 2221\u20132226 (2013).","journal-title":"Genes Dev."},{"key":"63718_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan, R., Du, W. & Guo, W. EZH2: a novel target for cancer treatment. J. Hematol. Oncol. 13, 104 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"63718_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fimmu.2016.00407","volume":"7","author":"C Sautes-Fridman","year":"2016","unstructured":"Sautes-Fridman, C. et al. Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. Front Immunol. 7, 407 (2016).","journal-title":"Front Immunol."},{"key":"63718_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Sautes-Fridman","year":"2019","unstructured":"Sautes-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"63718_CR26","doi-asserted-by":"publisher","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher, T. N. & Thommen, D. S. Tertiary lymphoid structures in cancer. Science 375, eabf9419 (2022).","journal-title":"Science"},{"key":"63718_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13287-023-03287-7","volume":"14","author":"A Lotfy","year":"2023","unstructured":"Lotfy, A., AboQuella, N. M. & Wang, H. Mesenchymal stromal\/stem cell (MSC)-derived exosomes in clinical trials. Stem Cell Res Ther. 14, 66 (2023).","journal-title":"Stem Cell Res Ther."},{"key":"63718_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41392-023-01704-0","volume":"9","author":"F Tan","year":"2024","unstructured":"Tan, F. et al. Clinical applications of stem cell-derived exosomes. Signal Transduct. Target Ther. 9, 17 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"63718_CR29","doi-asserted-by":"crossref","unstructured":"Lee, B. C., Kang, I. & Yu, K. R. Therapeutic features and updated clinical trials of mesenchymal stem cell (MSC)-derived exosomes. J Clin Med 10 (2021).","DOI":"10.3390\/jcm10040711"},{"key":"63718_CR30","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/leu.2014.41","volume":"28","author":"L Kordelas","year":"2014","unstructured":"Kordelas, L. et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 28, 970\u2013973 (2014).","journal-title":"Leukemia"},{"key":"63718_CR31","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.chest.2023.06.024","volume":"164","author":"AL Lightner","year":"2023","unstructured":"Lightner, A. L. et al. Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for the treatment of respiratory failure from COVID-19: A randomized, placebo-controlled dosing clinical trial. Chest 164, 1444\u20131453 (2023).","journal-title":"Chest"},{"key":"63718_CR32","doi-asserted-by":"publisher","first-page":"8844730","DOI":"10.1155\/2020\/8844730","volume":"2020","author":"R Zhao","year":"2020","unstructured":"Zhao, R., Chen, X., Song, H., Bie, Q. & Zhang, B. Dual role of MSC-derived exosomes in tumor development. Stem Cells Int 2020, 8844730 (2020).","journal-title":"Stem Cells Int"},{"key":"63718_CR33","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1007\/s00018-019-03125-1","volume":"76","author":"A Naji","year":"2019","unstructured":"Naji, A. et al. Biological functions of mesenchymal stem cells and clinical implications. Cell Mol. Life Sci. 76, 3323\u20133348 (2019).","journal-title":"Cell Mol. Life Sci."},{"key":"63718_CR34","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1158\/1078-0432.CCR-13-2590","volume":"20","author":"G Di Caro","year":"2014","unstructured":"Di Caro, G. et al. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin. Cancer Res 20, 2147\u20132158 (2014).","journal-title":"Clin. Cancer Res"},{"key":"63718_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1158\/2326-6066.CIR-24-0299","volume":"13","author":"J Lehmann","year":"2025","unstructured":"Lehmann, J. et al. Tertiary lymphoid structures in pancreatic cancer are structurally homologous, share gene expression patterns and b-cell clones with secondary lymphoid organs, but show increased T-cell activation. Cancer Immunol. Res 13, 323\u2013336 (2025).","journal-title":"Cancer Immunol. Res"},{"key":"63718_CR36","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke, L. et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat. Cancer 2, 794\u2013802 (2021).","journal-title":"Nat. Cancer"},{"key":"63718_CR37","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1535-6108(03)00309-X","volume":"4","author":"SR Hingorani","year":"2003","unstructured":"Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437\u2013450 (2003).","journal-title":"Cancer Cell"},{"key":"63718_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","volume":"19","author":"CA Chambers","year":"2001","unstructured":"Chambers, C. A., Kuhns, M. S., Egen, J. G. & Allison, J. P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev. Immunol. 19, 565\u2013594 (2001).","journal-title":"Annu Rev. Immunol."},{"key":"63718_CR39","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/353180a0","volume":"353","author":"A Rahemtulla","year":"1991","unstructured":"Rahemtulla, A. et al. Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature 353, 180\u2013184 (1991).","journal-title":"Nature"},{"key":"63718_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27349-7","volume":"12","author":"Y Deng","year":"2021","unstructured":"Deng, Y. et al. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nat. Commun. 12, 7041 (2021).","journal-title":"Nat. Commun."},{"key":"63718_CR41","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/15384047.2017.1281499","volume":"18","author":"S Yang","year":"2017","unstructured":"Yang, S. et al. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer. Cancer Biol. Ther. 18, 158\u2013165 (2017).","journal-title":"Cancer Biol. Ther."},{"key":"63718_CR42","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nprot.2013.023","volume":"8","author":"R Blecher-Gonen","year":"2013","unstructured":"Blecher-Gonen, R. et al. High-throughput chromatin immunoprecipitation for genome-wide mapping of in vivo protein-DNA interactions and epigenomic states. Nat. Protoc. 8, 539\u2013554 (2013).","journal-title":"Nat. Protoc."},{"key":"63718_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jsb.2006.05.009","volume":"157","author":"G Tang","year":"2007","unstructured":"Tang, G. et al. EMAN2: an extensible image processing suite for electron microscopy. J. Struct. Biol. 157, 38\u201346 (2007).","journal-title":"J. Struct. Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63718-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63718-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63718-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:32:21Z","timestamp":1759249941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63718-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["63718"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-63718-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AM is a consultant for Tezcat Biosciences and is named on a patent that has been licensed to Thrive Earlier Detection (an Exact Sciences company). CH reports research funding to the institution from Sanofi, Avenge, Iovance, KSQ, Theolytics, BTG, Novartis, 280Bio, Astrazeneca, EMD Serono, Takeda, Obsidian, Genentech, BMS, Summit Therapeutics, Artidis, and Immunogenesis, and personal fees from Regeneron and stock options from Briacell outside the submitted work. LMSS reports research support from Theolytics, advisory role\/consulting fees from BioNTech, and travel support from 10x Genomics, all outside the scope of this work. MD Anderson Cancer Center, VSK, ES, MM, RK hold a patent in the area of exosome biology. Patents related to EVs and Exosomes have been licensed to PranaX, Inc. VSK and RK are stock equity holders in PranaX, Inc. VSK and RK are founders, stock owners, and scientific consultants to PranaX, Inc. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8696"}}